NanoTherix

NanoTherix is a biotech company developing next-generation cancer therapies for hard-to-treat tumors such as glioblastoma (GBM). Our fully owned technology platform transforms nanobodies into superior Nanobody–Drug Conjugates (NDCs), overcoming the key limitations of conventional ADCs and enabling deeper tumor penetration, cleaner biodistribution, and broader therapeutic impact.